Psychedelic Integration Therapy

A recent term with an older backdrop

A 2022 concept analysis in Frontiers in Psychology says integration has drawn growing attention in recent years despite a long history of only brief mention. Its authors report that most published integration models date from 2017 onward and that their searches, which ran through August 2021, were not a systematic review of research. A 2023 article by an international group of clinicians notes that psychedelics have been used in various civilizations and explored scientifically for more than a century, but it presents integration as a distinct set of practices tied to the current expansion of psychedelic use.

From trial protocols to community services

In clinical trials, integration is the closing phase of a three-part model that also includes preparation and a dosing session. A 2024 Cochrane review made integrative therapeutic sessions a condition for including a trial, and describes them as sessions that debrief the experience and link its insights to everyday life.

Outside trials, a chapter drawing on an integration and support service run by ICEERS, an ethnobotanical education and research organization in Barcelona, says the term is used across clinical, neo-shamanic, traditional and recreational settings. Its author states that the term is widely accepted but has no precise definition. The service has operated since 2012, according to the chapter.

Guidelines written to fill a training gap

A 2023 guidelines article for mental health specialists says current graduate training in psychiatry, psychology and psychotherapy does not adequately prepare professionals for people who need support after psychedelic experiences. An international, bottom-up project produced the guidelines through literature reviews and roundtable discussions. The authors write that the team's own backgrounds shaped the content and suggest that later work use formal consensus methods.

Competing definitions

The 2022 concept analysis proposes a synthesized definition: an active, ongoing process of revisiting a psychedelic experience, making sense of it, translating its content and carrying what was learned into daily life. The 2023 guidelines instead describe integration as a clinical practice that deliberately facilitates processing of the content or consequences of an experience, without dismissing the experience's felt reality. A third group defines it as practices that either minimize harms or maximize benefits linked to psychedelic use.

Service, personal process and research construct

The concept analysis says integration services are offered by therapists, coaches and other practitioners, and that integration may also be self-guided. The word therapy in the page title therefore covers only one provider type among several. In research, a 2022 scale-development study uses integration to mean the post-acute period after drug administration and measures two things: behavioral engagement with integration and the felt sense of being integrated. Its authors report initial support for the scales' validity and reliability.

Neighboring terms

Psychedelic-assisted therapy is the wider term for treatment that combines a substance session with preparatory and integrative sessions, and integration is one phase of it. Aftercare and harm reduction are used in community settings for overlapping support; a 2025 study of peer groups frames integration groups as aftercare that may reduce harm. These labels are not interchangeable, and the sources do not show that practices under them are equivalent.

Sessions in clinical models

The 2023 guidelines describe an early stage of up to about five one-hour sessions. It covers basic support, building the working relationship, screening for conditions that need medical care, psychoeducation and goal setting, with stabilizing adverse effects as the priority. A later stage involves deeper work on the experience's content and on keeping insights in daily life, and may continue as regular psychotherapy. Approaches named include acceptance and commitment therapy, internal family systems and trauma-informed methods, drawn from existing psychotherapies.

A wide range of supportive practices

The concept analysis catalogs practices that people and practitioners place under integration: creative arts, music, movement and somatic work, journaling, meditation and mindfulness, time in nature, rest, ritual and shared reflection with others. Its authors place these on continuums such as conscious to unconscious and passive to active, and caution that the categories may reflect a Western worldview. Some of the listed methods come from Indigenous practices, and the authors note that none of the model authors appear to identify as Indigenous.

Peer and group formats

A qualitative survey of 65 people who had used psychedelics and attended integration groups, mostly in the United Kingdom, found that participants valued an accepting setting and meeting others with similar experiences. The participants were recruited online, were mostly women and were well educated. Groups can be run by facilitators of varying training, and the study reports that participants wanted facilitators with stronger clinical knowledge.

Stated aims

Authors who write about integration describe its aims as grounding benefits that arise from a psychedelic experience and addressing the challenges that arise from it. The concept analysis adds a broader aim of greater balance in mind, body, relationships and lifestyle. These are aims stated by practitioners and researchers who support the practice, and they are not outcomes that have been measured in controlled studies of integration.

Why people seek it

In the peer-group survey, people said they attended to feel less alone, to deepen their understanding and to get support after difficult experiences. The ICEERS chapter lists the profiles of people who sought its service: lack of preparation, unresolved experiences, difficulty with facilitators, traumatic episodes, worsening of an existing mental disorder, newly surfacing traumatic memories, repeated use without integration, and a perception of being attacked or possessed by entities. The list reflects one service's caseload and not the general population.

Little direct testing of integration itself

A 2023 call for evidence-based integration states that proposed models are theory-driven or have a history of clinical use, but that none has empirical support and so none can be called evidence based. The 2023 guidelines authors report that a systematic search found only one peer-reviewed article specifically on integration, which led them to include books and clinical manuals. They add that no evidence-based intervention is known for trauma symptoms caused by psychedelic experiences.

Trials of psychedelic-assisted therapy that included integration

The 2024 Cochrane review included six randomized trials with 149 participants who had life-threatening illness, tested in outpatient settings in the United States and Switzerland. For classical psychedelics, it found low-certainty evidence of lower anxiety and depression than with active placebo; for MDMA, from one trial of 18 people, results were very uncertain. All six trials were judged at high risk of bias, partly because participants could tell which substance they had received.

Every included trial contained integration sessions, and the review did not compare different amounts or types of integration. It follows, as an inference from the inclusion criteria and not a statement by the authors, that these results cannot show how much integration itself contributed. They also should not be carried over to other conditions or to use outside a trial.

Measures and group studies

Two integration scales were developed in 2022 and reported as valid and reliable in initial testing, which offers a way to measure the construct in later studies. The peer-group survey found that most respondents said the groups met their needs at least somewhat, but it was cross-sectional, self-reported, small and drawn from volunteers, so it cannot show that groups change outcomes.

Adverse events recorded in trials

The Cochrane review reports no treatment-related serious adverse events in the included trials, and it lists as common minor to moderate effects of classical psychedelics raised blood pressure, nausea, anxiety, emotional distress and psychotic-like symptoms. For MDMA the common effects were anxiety, dry mouth, jaw clenching and headache. Most symptoms eased as drug effects wore off or within about a week. These events arose in sessions that combined a substance with therapy, so they do not describe integration sessions alone.

Distress, screening and delayed care

The 2023 guidelines advise caution or avoidance for people with psychotic, bipolar or borderline personality disorders and for several medical conditions, and advise psychiatric referral when symptoms suggest psychosis or a persisting perceptual disorder. They also note that people may be more suggestible for roughly six to eight weeks after an experience, so non-consented or dogmatic interventions should be avoided.

A 2025 case report describes one psychologist in an unregulated facilitator training program who developed prolonged insomnia, depression and suicidal thoughts after repeated psilocybin use. Her trainers framed the distress as failed integration or spiritual rebirth and discouraged psychiatric care, and the authors say this delayed treatment. A single case cannot establish how common this is.

Boundary violations and abuse

A 2026 chapter on touch in psychedelic-assisted therapy says that recent reports of boundary violations and abuse have sharpened the debate about physical contact with people in altered states. A 2025 interview study of 16 trial researchers refers to media coverage of ethical violations in an MDMA trial without describing specific incidents, and distinguishes boundary crossings from violations. Researchers said some trials added a neutral person outside the treatment team for participants to contact, and they asked for clearer consent rules and training. Those interviews concerned dosing sessions, and the sources reviewed do not document the extent of such harms in integration work.

Facilitator competence, groups and care boundaries

In the peer-group survey, participants described dominant members, overwhelming trauma stories and members in serious distress whom the group was not equipped to help. The guidelines authors say existing training is mostly postgraduate. The sources reviewed identify no register or protected title specific to integration. This page is not a substitute for care, and new or worsening distress, sleep loss or thoughts of self-harm call for assessment by a licensed clinician or emergency services.